Vertex Pharmaceuticals is buying an endocrine treatment specialist for $10 billion.

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

One of the questions I get more than any other is, “Jonathan, how do you know these stocks will explode when you find them?” The honest answer is, I don’t. Nobody knows ahead of time that a stock is ...

Michael Yee, UBS biotech analyst, joins 'The Exchange' to discuss Yee's thoughts on biotech stocks, what's driving the ...

PJP delivered stronger 5-year returns with lower volatility, while FBT offers broader biotech exposure at a slightly cheaper ...

It has been a banner year for biotech buyouts, and these are two of the prime targets.

Biotech investors are finally getting something they haven't seen in years: a friendlier macro environment. Interest rates appear to be stabilizing, FDA activity is picking up again, and large ...

In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector’s two major indexes — the SDPR S&P Biotech ETX (NYSE: XBI) and iShares Biotech ETF (NYSE: IBB) — ...

That is a big risk investors take when trying to find the winners and losers within the biotech sector. While we made the ...

Shares of Profusa (PFSA) hit a record low on Thursday, crashing 28% after the biotech company announced its second reverse ...